AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 131 min read$AEHR

Erickson Gayn sold $5.2M of AEHR (indirect holdings)

Erickson Gayn (President and CEO) sold 40,000 indirectly-held shares of AEHR TEST SYSTEMS (AEHR) at an average of $130.84 ($130.79–$132.27, $5.23M total) across 2 trades on 2026-08-12.

Original reporting
SEC EDGAR · Erickson Gayn
Published Aug 13, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 10:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AEHR
Neutral
medium confidence
Mentioned
$AEHR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEHRNeutralLow
01

Why it matters

Traders may monitor for follow-on insider activity or unusual selling patterns, but this filing alone does not change AEHR’s operating outlook.

02

Market read

A $5.23M CEO sale is disclosed, but there is no new fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs; the filing does not provide intent or linkage to company performance.

Relevance 6/10Novelty 3/10Timing: filed after-hours on 2026-08-13, covering sales on 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for AEHR, reported by CEO Erickson Gayn as an indirect holding sale.

Company-level read

Ticker impact

$AEHRNeutralMedium confidence
Context

AEHR CEO Erickson Gayn sold $5.23M of AEHR shares via open-market sales, reducing holdings to 157,723 shares.

Expected impact

Likely limited near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

Form 4 shows sale size and pricing range, but provides no earnings, guidance, deal, or regulatory catalyst. Insider sales are common and often non-informational, though the absence of a stated 10b5-1 plan can add minor uncertainty.

Market effects

Sector

No clear sector read-through from a single insider sale without accompanying corporate or regulatory developments.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The CEO’s sale without a stated 10b5-1 plan could be interpreted as higher near-term risk tolerance or liquidity need, potentially weighing on sentiment.

Key entities

  • issuer
    AEHR

    AEHR Test Systems, the company whose shares were sold by its CEO.

  • insider
    Erickson Gayn

    President and CEO of AEHR, reporting open-market sales of shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AEHR insider trading history →

Related articles

SEP 25
$AEHRHigh

AEHR Stock Jumps As Oppenheimer Targets AI Test Boom

Aehr Test Systems (AEHR) stock rose 7.06% on strong semiconductor test demand and AI-driven growth prospects. Oppenheimer initiated an Outperform rating with a $120 target, citing a $41M hyperscaler order. AEHR reported $18.8M revenue, $1.39M net income, and a strong balance sheet. The stock has gained 32% in a month, driven by AI and EV themes.

stockstotrade.com2 min
SEP 4
$AEHRMed

AEHR Stock Rides AI Order Wave Amid Volatility

Aehr Test Systems (AEHR) stock rose 13.28% following strong earnings and a positive outlook for semiconductor test demand. The company reported $50M in revenue, $18.8M in quarterly revenue, and a net income of $1.39M. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI production. The stock has shown volatility, with a recent drop of 9.5-10.5% in a single session. Insiders have sold shares but maintain significant holdings. AEHR is actively presenting a

stockstotrade.com2 min
SEP 4
$AEHRHigh

AEHR Stock Rallies As AI Orders And Wall Street Support Build

Aehr Test Systems (AEHR) stock rose 11.71% due to strong AI-related demand. The company reported $18.8M in revenue with a 35.3% gross margin. Jefferies initiated coverage with a Buy rating and $175 price target, citing AEHR's role in AI chip production. The company has a strong balance sheet and a $22M follow-on order from a major customer.

stockstotrade.com2 min